- Blood plasma & plasma derived medicinal products are gaining prominence due to their critical role in treating a wide range of rare and chronic conditions, such as immunodeficiencies, hemophilia, and autoimmune disorders, as well as their expanding use in emergency medicine and critical care
- The increasing prevalence of rare diseases and chronic immune-related disorders, coupled with rising awareness about plasma therapies and advancements in plasma fractionation technologies, is driving the North America demand for plasma-derived medicinal products
- U.S. dominates the blood plasma & plasma derived medicinal products market, holding the largest revenue share of 64.30% in 2024, attributed to rising healthcare expenditures, growing patient population, supportive government regulations, and increasing penetration of international plasma product
- U.S. is also projected to be the fastest-growing country in the market during the forecast period, driven by infrastructure development in healthcare, growing access to plasma donation and collection facilities, and strong investments in biotechnology and healthcare R&D
- The immunoglobulins segment is expected to dominate the blood plasma & plasma derived medicinal products market with a market share of 41.40% in 2025, owing to its widespread use in treating immunodeficiency diseases, inflammatory conditions, and neurological disorders, alongside increasing North America awareness and regulatory approvals
